Investor Relations

Latest News

Thu Dec 12, 2024 08:30 am

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Tue Dec 3, 2024 07:30 am

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Thu Nov 21, 2024 07:00 am

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

View All News

In the News

ABC7 Exclusive: New study reveals promising results for age reversal pill on dogs
Latest Presentation
All Presentations

LATEST FINANCIAL RESULTS

Q2 2024

Quarter Ended Jun 30, 2024

10-Q

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

LATEST ANNUAL FILING

For Fiscal Year Ending Dec 31, 2023
View 10-K

Company Overview

At Telomir Pharmaceuticals, we are committed to developing breakthrough science to address the root causes of difficult to treat diseases. By partnering with the brightest minds in science and healthcare, we have the potential to discover and develop ground-breaking treatments to bring about better health for patients and change the future of medicine.

View Management Team
View Board of Directors
Symbol
NASDAQ: TELO
Price
$
Volume
Change
{'1d_range' | i8ln tLang}
{scope.data.dayLow | asQHLast tLang}
{scope.data.dayHigh | asQHLast tLang}
{'52weekrange' | i8ln tLang}
{scope.data.week52Low | asQHLast tLang}
{scope.data.week52High | asQHLast tLang}

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

IR Contacts

Headquarters

Telomir Pharmaceuticals, Inc.
900 West Platt St.
Suite 200
Tampa, FL 33606-2173
United States
T: 813-864-2558
[email protected]

Investor Relations

Telomir Pharmaceuticals, Inc.
900 West Platt St.
Suite 200
Tampa, FL 33606-2173
United States
T: 813-864-2558
[email protected]

Transfer Agent

Equiniti
6201 15th Avenue.
Brooklyn, NY 11219
T: US 800-401-1957
T: Canada/US Virgin Islands 800-468-9716
T: Other Internationl Access Codes
[email protected]